Description: bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Home Page: www.bioaffinitytech.com
BIAF Technical Analysis
22211 West Interstate 10
San Antonio,
TX
78257
United States
Phone:
210 698 5334
Officers
| Name | Title |
|---|---|
| Mr. Steven Girgenti | Founder & Executive Chairman of the Board |
| Ms. Maria Zannes J.D. | Founder, President, CEO & Director |
| Mr. J. Michael Edwards CPA, M.B.A. | CFO & Principal Accounting Officer |
| Mr. Xavier T. Reveles M.S. | Chief Operating Officer |
| Dr. William Bauta Ph.D. | Chief Science Officer |
| Mr. Timothy P. Zannes J.D. | Executive VP, Secretary & General Counsel |
| Ms. Julie Anne Overton | Director of Communications |
| Mr. Dallas J. Coleman | Vice President of sales |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.8626 |
| Price-to-Sales TTM: | 2.0744 |
| IPO Date: | 2022-09-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 75 |